Fridha Viridiana Villalpando-Vargas1, Juan José Rivera-Valdés2, Anabell Alvarado-Navarro3, Selene Guadalupe Huerta-Olvera4, José Macías-Barragán5, Erika Martínez-López2, Omar Graciano-Machuca6. 1. Laboratory of Neurophysiology, Department of Cellular and Molecular Biology Sciences, Biologic and Agropecuary Sciences Campus, University of Guadalajara (UDG), Zapopan, Jalisco, Mexico. 2. Institute of Translational Nutrigenetics and Nutrigenomics, Department of Molecular Biology and Genomics, Health Sciences Campus (CUCS), University of Guadalajara (UDG), Guadalajara, Jalisco, Mexico. 3. Research Center in Immunology and Dermatology, Department of Physiology, Health Sciences Campus (CUCS), University of Guadalajara (UDG), Guadalajara, Jalisco, Mexico. 4. Department of Medical and Life Sciences, University of Guadalajara (UDG), La Ciénega Campus, Ocotlan, Jalisco, Mexico. 5. Laboratory of Biological Systems, Department of Health Sciences, Los Valles Campus, University of Guadalajara (UDG), Ameca, Jalisco, Mexico. 6. Laboratory of Biological Systems, Department of Health Sciences, Los Valles Campus, University of Guadalajara (UDG), Ameca, Jalisco, Mexico. omargmachuca@gmail.com.
Abstract
BACKGROUND: Psoriasis (Ps) is a chronic dermatosis characterized by erythematous-squamous plaques derived from an inflammatory response. The effect of polymorphisms in the genes that encode the members of the IL-17 family and their receptors has been studied to find an association with the susceptibility to Ps. However, the findings have not been conclusive. OBJECTIVES: To describe the association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to Ps. METHOD: A systematic review was conducted using the PubMed and Scopus databases to identify studies that evaluated the association between IL-17A, IL-17F, and IL-17RA gene polymorphisms and Ps susceptibility. This meta-analysis included reports published until June 2021. Heterogeneity was assessed using Cochran's Q-statistic test and I2 statistics. The associations between polymorphisms and Ps susceptibility were determined by pooled OR with a 95% CI. RESULTS: Fifteen studies were included. The frequency of the T allele of the IL-17F rs763780 polymorphism was significantly lower in patients with vulgar Ps (OR = 0.732, p = 0.026). The TT genotype of the IL-17F rs763780 polymorphism was significantly associated with a decreased frequency in individuals with Ps and psoriatic arthritis (PsA) (TT:TC + CC OR = 0.664, p = 0.046). Regarding IL-17RA polymorphisms, the AG genotype of the rs4819554 polymorphism showed a near-significant decrease in psoriasis risk compared to the GG genotype (AG:GG OR = 0.604, p = 0.050). Other polymorphisms in IL-17A, IL-17F and IL-17RA showed no association with Ps. CONCLUSIONS: The T allele and TT genotype of the IL-17F rs763780 polymorphism may be associated with a decreased risk of psoriasis. Therefore, the implications of this variant on psoriasis pathogenesis and treatment require further investigation.
BACKGROUND: Psoriasis (Ps) is a chronic dermatosis characterized by erythematous-squamous plaques derived from an inflammatory response. The effect of polymorphisms in the genes that encode the members of the IL-17 family and their receptors has been studied to find an association with the susceptibility to Ps. However, the findings have not been conclusive. OBJECTIVES: To describe the association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to Ps. METHOD: A systematic review was conducted using the PubMed and Scopus databases to identify studies that evaluated the association between IL-17A, IL-17F, and IL-17RA gene polymorphisms and Ps susceptibility. This meta-analysis included reports published until June 2021. Heterogeneity was assessed using Cochran's Q-statistic test and I2 statistics. The associations between polymorphisms and Ps susceptibility were determined by pooled OR with a 95% CI. RESULTS: Fifteen studies were included. The frequency of the T allele of the IL-17F rs763780 polymorphism was significantly lower in patients with vulgar Ps (OR = 0.732, p = 0.026). The TT genotype of the IL-17F rs763780 polymorphism was significantly associated with a decreased frequency in individuals with Ps and psoriatic arthritis (PsA) (TT:TC + CC OR = 0.664, p = 0.046). Regarding IL-17RA polymorphisms, the AG genotype of the rs4819554 polymorphism showed a near-significant decrease in psoriasis risk compared to the GG genotype (AG:GG OR = 0.604, p = 0.050). Other polymorphisms in IL-17A, IL-17F and IL-17RA showed no association with Ps. CONCLUSIONS: The T allele and TT genotype of the IL-17F rs763780 polymorphism may be associated with a decreased risk of psoriasis. Therefore, the implications of this variant on psoriasis pathogenesis and treatment require further investigation.
Authors: Gurdeep S Sagoo; Rachid Tazi-Ahnini; Jonathan W N Barker; James T Elder; Rajan P Nair; Lena Samuelsson; Heiko Traupe; Richard C Trembath; Darren A Robinson; Mark M Iles Journal: J Invest Dermatol Date: 2004-06 Impact factor: 8.551
Authors: R C Trembath; R L Clough; J L Rosbotham; A B Jones; R D Camp; A Frodsham; J Browne; R Barber; J Terwilliger; G M Lathrop; J N Barker Journal: Hum Mol Genet Date: 1997-05 Impact factor: 6.150